Risk factors for dysgeusia during chemotherapy for solid tumors: a retrospective cross-sectional study

Malta, Cássia Emanuella Nóbrega; Martins, Joyce Ohana de Lima; Carlos, Anna Clara Aragão Matos; Freitas, Milena Oliveira; Magalhães, Iana Aragão; Vasconcelos, Hérica Cristina Alves de; Silva-Fernandes, Isabelly Joyce de Lima; Silva, Paulo Goberlânio de Barros

doi:10.1007/s00520-021-06219-4

Cited by 7 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The process of neurotransmission can be impacted in an indirect manner where cranial nerves are destroyed, afferent pathways are modified due to the passage of cytotoxic drugs through the blood-brain barrier, or as a consequence of neuropathy induced by chemotherapy, according to previous research [ 30 ]. In an alternative scenario, taste perception may be modified in an indirect manner as a result of chemotherapy-induced impairment of brain regions that regulate taste perception [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

“…However, the mean score pattern is quite fluctuating. A previous study showed that TAs were associated with the number of cycles of chemotherapy in an increasing manner [ 11 ]. Another study reported that patients’ ability to taste decreased directly after the first round of chemotherapy [ 14 ], and patients were found to have more severe taste impairments at the beginning of the treatment compared to the subsequent rounds [ 49 ].…”

Section: Discussionmentioning

confidence: 99%

“…Smokers and older patients were less affected by chemotherapy-induced taste impairments due to their increased taste thresholds [ 2 , 10 ]. On the other hand, women were found to be more susceptible to dysgeusia than men [ 11 , 12 ]. Developing dysgeusia was significantly associated with the type of cancer and the chemotherapy regimen [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

“…Similarly, gynecological cancer patients also showed a greater incidence of TAs [ 4 ]. Furthermore, it was observed that the number of chemotherapy cycles were associated with TA [ 4 , 11 , 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Taste alteration and its relationship with nutritional status among cancer patients receiving chemotherapy, cross-sectional study

Al-Amouri,

Badrasawi

2024

PLoS ONE

View full text Add to dashboard Cite

The aim of this study is to determine the prevalence of taste alterations (TAs) during chemotherapy and their association with nutritional status and malnutrition. In addition to the associated factors with TA, including sociodemographic health-related factors and clinical status, and to investigate coping strategies to manage TA. A multicenter cross-sectional design study was conducted on 120 cancer patients aged at least 18 who had been undergoing at least one round of chemotherapy. TAs were evaluated using the chemotherapy-induced taste alteration scale (CiTAS), the malnutrition universal screening tool (MUST) was used for nutritional screening, the antineoplastic side effects scale (ASES) was used for subjective assessment of chemotherapy side effects, and the Charlson comorbidity index (CCI) was used for comorbidity assessment. SPSS21 software was used to analyze the data, and the independent T-test and one-way ANOVA test were used to determine the association between TAs and a variety of related variables. The prevalence of TAs was 98.3%. Among participants, 48.3% were at low risk of malnutrition, 20% at medium risk, and 31.7% at high risk. Malnutrition risk was associated with taste disorders (p<0.05). Patients’ age, gender, educational level, and physical status were associated with TAs (p<0.05). Type of cancer, chemotherapy regimen, and number of chemotherapy cycles were also associated with TAs (p<0.05). A variety of antineoplastic side effects were associated with TAs (p<0.05), including nausea, vomiting, dry mouth, sore mouth and throat, excessive thirst, swallowing difficulty, appetite changes, weight loss, dizziness, lack of energy, disturbed sleep, anxiety, and difficulty concentrating. TAs were associated with an increased number of comorbidities, and individuals with diabetes, pulmonary diseases, and hypertension were associated with TAs (P<0.05). Patients in this study rarely practice self-management strategies to cope with TAs. A high prevalence (98.3%) of TAs in cancer patients receiving chemotherapy was found, and it was linked to a variety of negative outcomes. Chemotherapy-induced TAs are an underestimated side effect that requires more attention from patients and health care providers.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Taste alteration and its relationship with nutritional status among cancer patients receiving chemotherapy, cross-sectional study

Al-Amouri,

Badrasawi

2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Dysgeusia is a prominently subjective gustatory disturb that may occur during chemotherapies and affect patients adherence to treatment and quality of life with severe implications on clinical outcome [ 1 , 2 ]. Therefore, physicians should thoroughly monitor the occurrence of any taste alteration in order to undertake strategies to address it and at the same time not compromise the therapeutic goal.…”

Section: Introductionmentioning

confidence: 99%

Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire

Camela,

Villani,

Ocampo Garza

et al. 2023

Dermatol Pract Concept

View full text Add to dashboard Cite

Introduction: Dysgeusia may occur during conventional or target-therapies and affect patients adherence-to-treatment. Therefore, it should be monitored to improve clinical outcome. To date, available questionnaires on dysgeusia relate to traditional antineoplastics and do not apply to target-therapies as the pathogenetic mechanism and clinical expression differ. Objectives: To develop a patient-reported outcome measure (PROM) to screen for and monitor the occurrence and severity of dysgeusia in patients under Smoothened (SMO) inhibitors: the SMO-iD questionnaire. Methods: Patients with locally advanced basal cell carcinomas referring dysgeusia under SMO inhibitors at the University Hospital of Naples Federico II, were enrolled between January-December 2020. The PROM was elaborated based on chemotherapy-induced dysgeusia (CiTas) scale (development phase) and then validated by measuring internal consistency and reliability (validation phase). Results: Thirty-nine patients were enrolled and interviewed every 8 weeks. In the first phase, 160 CiTas questionnaires were collected, and the SMO-iD questionnaire was developed. In the second phase, 195 SMO-iD questionnaires were recorded, and reliability and validity assessed. Cronbach alpha was 0.89. Conclusions: The SMO-iD questionnaire is a validated questionnaire that shows high face and content validity as well as high internal consistency and reliability. Hence, it may be introduced in daily clinical setting to monitor dysgeusia in patients under SMO-inhibitors.

show abstract

Heterogeneity of vulnerability and taste changes in older cancer patients undergoing chemotherapy: a latent class analysis

Zhu

Wang

Sun

et al. 2023

Support Care Cancer

View full text Add to dashboard Cite

Risk factors for dysgeusia during chemotherapy for solid tumors: a retrospective cross-sectional study

Cited by 7 publications

References 32 publications

Taste alteration and its relationship with nutritional status among cancer patients receiving chemotherapy, cross-sectional study

Taste alteration and its relationship with nutritional status among cancer patients receiving chemotherapy, cross-sectional study

Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire

Heterogeneity of vulnerability and taste changes in older cancer patients undergoing chemotherapy: a latent class analysis

Contact Info

Product

Resources

About